Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Hou, Panpan ^a   Chen, Shuliang ^a   Wang, Shilei ^a   Yu, Xiao ^a   Chen, Yu ^a   Jiang, Meng ^b   Zhuang, Ke ^c   Ho, Wenzhe ^c   Hou, Wei ^a   Huang, Jian ^d   Guo, Deyin ^a  

^a WUHAN UNIVERSITY   (China)

^b RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^c WUHAN UNIVERSITY   (China)

^d TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4;

ALLELE; ANIMAL; CD4+ T LYMPHOCYTE; CELL CULTURE; CELL LINE; CELL MEMBRANE; CRISPR CAS SYSTEM; DISEASE RESISTANCE; GENE DELETION; GENE EXPRESSION; GENE LOCUS; GENE TARGETING; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JURKAT CELL LINE; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; RHESUS MONKEY; RNA EDITING; VIROLOGY;

ALLELES; ANIMALS; BASE SEQUENCE; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CELL MEMBRANE; CELLS, CULTURED; CRISPR-CAS SYSTEMS; DISEASE RESISTANCE; GENE DELETION; GENE EXPRESSION; GENE TARGETING; GENETIC LOCI; HIV INFECTIONS; HIV-1; HUMANS; JURKAT CELLS; MACACA MULATTA; MOLECULAR SEQUENCE DATA; RECEPTORS, CXCR4; RNA EDITING;

EID: 84944916655     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep15577     Document Type: Article

References (48)

1. Carbone, A. et al. Diagnosis and management of lymphomas and other cancers in HIV-infected patients. Nat Rev Clin Oncol. 11, 223-238 (2014).
2. Gulick, R. M. et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 337, 734-739 (1997).
3. Hammer, S. M. et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 337, 725-733 (1997).
4. Perelson, A. S. et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature. 387, 188-191 (1997).
5. Larder, B. A., Darby, G., Richman, D. D. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243, 1731-1734 (1989).
6. Wong, J. K. et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278, 1291-1295 (1997).
7. Dalgleish, A. G. et al. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312, 763-767 (1984).
8. Alkhatib, G. et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science. 272, 1955-1958 (1996).
9. Bleul, C. C. et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 382, 829-833 (1996).
10. Liu, R. et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 86, 367-377 (1996).
11. Lim, J. K. et al. CCR5 deficiency is a risk factor for early clinical manifestations of West Nile virus infection but not for viral transmission. J Infect Dis. 201, 178-185 (2010).
12. Connor, R. I., Sheridan, K. E., Ceradini, D., Choe, S., Landau, N. R. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med. 185, 621-628 (1997).
13. Allers, K. et al. Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem cell transplantation. Blood. 117, 2791-2799 (2011).
14. Tebas, P. et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med. 370, 901-910 (2014).
15. Didigu, C. A. et al. Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and cxcr4 protects CD4+ T cells from HIV-1 infection. Blood. 123, 61-69 (2014).
16. Hsu, P. D., Lander, E. S., Zhang, F. Development and Applications of CRISPR-Cas9 for Genome Engineering. Cell. 157, 1262-1278 (2014).
17. Wang, T., Wei, J. J., Sabatini, D. M.& Lander, E. S. Genetic screens in human cells using the CRISPR-Cas9 system. Science 343, 80-84 (2014).
18. Niu, Y. et al. Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. Cell. 156, 836-843 (2014).
19. Shalem, O. et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343, 84-87 (2014).
20. Barnes, D. E. Non-homologous end joining as a mechanism of DNA repair. Curr Biol. 11, R455-7 (2001).
21. van den Bosch, M., Lohman, P. H.,& Pastink, A. DNA double-strand break repair by homologous recombination. Biol Chem. 383, 873-892 (2002).
22. Lieber, M. R. The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annu Rev Biochem. 79, 181-211 (2010).
23. Mandal, P. K. et al. Efficient Ablation of Genes in Human Hematopoietic Stem and Effector Cells using CRISPR/Cas9. Cell stem cell. 15, 643-652 (2014).
24. Ye, L. et al. Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Delta32 mutation confers resistance to HIV infection. Proc Natl Acad Sci USA 111, 9591-9596 (2014).
25. Cecilia, D. et al. Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage. J Virol. 72, 6988-6996 (1998).
26. Tempaku, A. Inhibition of human immunodeficiency virus type-1 (HIV-1) replication at a reverse transcription step by human cell factor(s). Biol Pharm Bull. 28, 893-897 (2005).
27. Dar, A., Kollet, O., Lapidot, T. Mutual, reciprocal SDF-1/CXCR4 interactions between hematopoietic and bone marrow stromal cells regulate human stem cell migration and development in NOD/SCID chimeric mice. Exp Hematol. 34, 967-975 (2006).
28. Nagasawa, T. et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 382, 635-638 (1996).
29. Liu, Y., Zhou, J., Pan, J. A., Mabiala, P., Guo, D. A Novel Approach to Block HIV-1 Coreceptor CXCR4 in Non-toxic Manner. Mol Biotechnol. 56, 890-902 (2014).
30. Lu, X., Xue, H., Ke, Z., Chen, Jin., Ji, Li. CRISPR-Cas9: a new and promising player in gene therapy. J Med Genet. 52, 289-96 (2015).
31. Hutter, G. et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 360, 692-698 (2009).
32. Holt, N. et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol. 28, 839-847 (2010).
33. Hofer, U. et al. Pre-clinical modeling of CCR5 knockout in human hematopoietic stem cells by zinc finger nucleases using humanized mice. J Infect Dis. 208 Suppl 2, S160-164 (2013).
34. DiGiusto, D. L. et al. RNA-based gene therapy for HIV with lentiviral vector-modified CD34 (+ ) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med. 2, 36ra43 (2010).
35. Wilkin, T. J. et al. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis. 44, 591-595 (2007).
36. Yuan, J. et al. Zinc-finger nuclease editing of human cxcr4 promotes HIV-1 CD4 (+ ) T cell resistance and enrichment. Mol Ther. 20, 849-859 (2012).
37. Wilen, C. B. et al. Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases. PLoS Pathog. 7, e1002020 (2011).
38. Qu, X. et al. Zinc-finger-nucleases mediate specific and efficient excision of HIV-1 proviral DNA from infected and latently infected human T cells. Nucleic Acids Res. 41, 7771-7782 (2013).
39. Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823 (2013).
40. Cradick, T. J., Fine, E. J., Antico, C. J., Bao, G. CRISPR/Cas9 systems targeting beta-globin and CCR5 genes have substantial off-target activity. Nucleic acids Res. 41, 9584-9592 (2013).
41. Ye, L. et al. Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Delta32 mutation confers resistance to HIV infection. Proc Natl Acad Sci USA 111, 9591-9596 (2014).
42. Wang, W. et al. CCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infection. PLoS One. 9, e115987 (2014).
43. Li, C. et al. Inhibition of HIV-1 infection of primary CD4+ T cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9. J Gen Virol (2015).
44. Jiang, W., Bikard, D., Cox, D., Zhang, F., Marraffini, L. A. RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nat Biotechnol. 31, 233-239 (2013).
45. Sun, X. et al. CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev. 29, 709-722 (2010).
46. Chung, S. H. et al. CXC chemokine receptor 4 expressed in T cells plays an important role in the development of collageninduced arthritis. Arthritis Res Ther. 12, R188 (2010).
47. Gao, G. et al. Inhibition of HIV-1 transcription and replication by a newly identified cyclin T1 splice variant. J Biol Chem. 288, 14297-14309 (2013).
48. Fu, Y., Sander, J. D., Reyon, D., Cascio, V. M., Joung, J. K. Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol. 32, 279-284 (2014).